乙型肝炎病毒包膜区和核心区CTL抗原表位变异对感染慢性化及疾病转归的影响*

doi:10.3969/.j.issn.1672-5069.2015.06.005

实用肝脏病杂志 ›› 2015, Vol. 18 ›› Issue (6): 581-584.doi: 10.3969/.j.issn.1672-5069.2015.06.005

乙型肝炎病毒包膜区和核心区CTL抗原表位变异对感染慢性化及疾病转归的影响^*

哈明昊，佘会元，吴建秋，孙莉萍，沈文娟，黄钟鸣，陈晓兰，单文艳，何慧芳

200137上海市浦东新区上海市第七人民医院感染性疾病科

收稿日期:2015-02-02 出版日期:2015-11-20 发布日期:2016-02-04
作者简介:哈明昊,男,39岁,博士研究生,副主任医师,科主任。主要从事病毒性肝炎诊断与治疗学研究。E-mail： hmh_1021@sina.com
基金资助:
*基金项目：浦东新区卫生系统学科带头人培养计划资助项目（编号：PWRd2011-06）; 上海市浦东新区卫生局卫生科技发展专项基金资助项目（编号：PW2012A-17）; 上海市卫生局科研课题基金资助项目（编号：20124368）; 上海市高级中西医结合人才培养计划资助项目（编号：ZY3-RCPY-4-2010）

Impact of CTL epitope mutations of hepatitis B virus envelope protein and core protein on chronicity and disease prognosis in patients with hepatitis B

Ha Minghao， She Huiyuan， Wu Jianqiu， et al.

Department of Infectious Diseases and Hepatology,7th People’s Hospital,Shanghai 200137,China

Received:2015-02-02 Online:2015-11-20 Published:2016-02-04

摘要/Abstract

摘要： 目的探讨HBV包膜区和核心区细胞毒性T淋巴细胞（CTL）抗原表位变异的规律及对疾病发展转归的影响。方法本研究选择无症状HBsAg携带者（ASC）38例,慢性乙型肝炎（CHB）35例,乙型肝炎肝硬化（LC）23例。采用DNA测序法检测HBV包膜区和核心区病毒序列及表位变异情况,并分析其与临床转归的关系。结果在入组患者中,HBV包膜区CTL抗原表位41~49、88~96、97~108、172~180和185~194变异率分别为48个（55.2%）、13个（14.9%）、11个（12.6%）、9个（10.3%）和6个（6.9%）;HBV CTL 41~49位变异率在CHB和肝硬化患者中的变异率分别为60.0%和65.2%,显著高于ASC[31.6%,P<0.05];HBV核心区CTL抗原表位18~27和91~95的变异率分别为18个（56.2%）和14个（43.8%）,HBV CTL18~27位的变异率在慢性乙型肝炎和肝硬化患者中分别为20.0%和30.4%,显著高于ASC[10.5%,P<0.05];多变量分析表明,HBV核心区CTL 41~49的变异是预示HBV感染后患者肝内炎症活动、慢性乙型肝炎病程进展、迁延并发生肝炎肝硬化的独立危险因素。结论HBV CTL变异是HBV感染慢性化的重要原因,预示病情将进展或加重。

关键词: 乙型肝炎, 细胞毒性T淋巴细胞, 抗原表位, 变异

Abstract: Objective To investigate the impact of cytotoxic T lymphocyte（CTL） epitope mutation of HBV envelope and core protein on disease progress in patients with hepatitis B. Methods 38 individuals with asymptomatic HBsAg carrier,35 patients with chronic hepatitis B and 23 with liver cirrhosis were recruited in this study. Gene sequencing analysis of HBV core region and envelope region was carried out in all enrolled patients to unveil any possible CTL epitope mutation. Results The mutation rates of locus 41~49,88~96,97~108,172~180 and 185~194 of CTL epitope in HBV envelope region were 48（55.2%）,13（14.9%）,11（12.6%）,9（10.3%） and 6（6.9%）,respectively;60% of mutation at locus 41~49 in patients with chronic hepatitis B and 65.2% in with liver cirrhosis were significantly higher than 31.6% in asymptomatic HBsAg carriers（P<0.05）;the mutation rates at 18~27 and 91~95 locus of CTL epitope in HBV core region were 56.2% and 43.8%,respectively;the mutation rates at locus 18~27 were also higher in patients with CHB（20.0%） and LC（30.4%） than that in asymptomatic HBsAg carriers （10.5%,P<0.05）;Multivariate analysis showed that locus 41~49 mutation was an independent risk factor for the progress of CHB to LC. Conclusion CTL epitope mutation of HBV is a significant cause for the chronicity of hepatitis B virus infection.

Key words: Hepatitis B, Mutation, Cytotoxic T lymphocytes, Epitope

哈明昊，佘会元，吴建秋，孙莉萍，沈文娟，黄钟鸣，陈晓兰，单文艳，何慧芳. 乙型肝炎病毒包膜区和核心区CTL抗原表位变异对感染慢性化及疾病转归的影响^*[J]. 实用肝脏病杂志, 2015, 18(6): 581-584.

Ha Minghao， She Huiyuan， Wu Jianqiu， et al.. Impact of CTL epitope mutations of hepatitis B virus envelope protein and core protein on chronicity and disease prognosis in patients with hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(6): 581-584.

参考文献

[1] Rizzetto M. Treatment of hepatitis B virus cirrhosis. Hepat Mon,2012,12（5）:309-311.
[2] Taheri HH,Hasanjani MR,Bijani AM,et al. Efficacy of hepatitis B vaccine in those who lost Hepatitis B surface antigen during follow-up:efficacy of HBV vaccine in those who lost HBsAg. Hepat Mon,2011,11（2）:119-122.
[3] Sitia G,Isogawa M,Kakimi K,et Al. Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proc Natl Acad Sci USA,2002,99（21）:13717-13822.
[4] Sitia G,Lannacone M,Mtiller S,et al. Treatment with HMGBl inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol,2007,81（1）：100-108.
[5] Nakamoto Y,Kaneko S. Analysis of intrahepatie lymphocyte subsets in a transgenic mouse model of immune-mediated hepatocarcinogenesis. J Exp Clin Cancer Res,2006,25（1）：55-63.
[6] Sobao YD,Sugi KI,omiyama HA,et al. Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*2402,the most common HLA class I allele in East Asia. J Hepatol,2001,34:922-929.
[7] Boettler TC,Spangenberg HC,Neumann HC,et al. T cells with a CD4 + CD25 + regulatory phenotype suppress in vitro proliferation of virus-specific CD8 + T cells during chronic hepatitis C virus infection. J Virol,2005,79:7860-7867.
[8] Zhang HR,Tang GI,Sun MM,et al. Molecular biological features and clinical significance of hepatitis B virus genotype in Nanjin. World J Infect,2004,4:232-234.
[9] Yan L,Hou JL,Jiang S,et al. A study on the relationship between HBV genotype and outcome of hepatitis B virus infection. J Chin Physicians,2004,6:1347-1348.
[10] Penna A,Chisari FV,Giuberti T,et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med,1991,174:1565-1570.
[11] Nayersina R,Fowler P,Schlicht HJ,et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol,1993,150:4659-4671.
[12] Daniel K,Kwang SL,Davey S,et al. Number of mutations within CTL-defined epitopes of the hepatitis B virus（HBV） core region is associated with HBV disease progression. J Med Virol,2011,83:2082-2087.
[13] 慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[14] 戴明佳,方圆 ,颜学兵,等. 740例HBV感染者血清HBV逆转录酶区耐药位点分析. 实用肝脏病杂志,2014,17（3）：255-258.
[15] Jianjun N,Shuizhen H,Chenghao S,et al. Variability of the S gene of hepatitis B virus in southeastern China. Arch Virol,2010,155: 1951-1957.

乙型肝炎病毒包膜区和核心区CTL抗原表位变异对感染慢性化及疾病转归的影响^*

Impact of CTL epitope mutations of hepatitis B virus envelope protein and core protein on chronicity and disease prognosis in patients with hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[7]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[8]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.
[9]	廖桂婵, 彭颉, 张小勇. 肝细胞介导的天然免疫应答参与控制乙型肝炎病毒感染^*[J]. 实用肝脏病杂志, 2019, 22(5): 617-619.
[10]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[11]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[12]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[13]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[14]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.
[15]	陈嵘, 黄美玲, 凌雪梅, 林小红, 曾俊, 黎云, 夏建红. 替比夫定联合HBIG和乙肝疫苗阻断HBV母婴传播临床效果分析*[J]. 实用肝脏病杂志, 2019, 22(5): 752-753.